Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 11, Issue 1, Pages 83-88
Clinical Gastroenterology

Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID

John H Hegarty,1,8 Lars Halvorsen,2 Bouke P Hazenberg,3 Andrzej Nowak,4 Colin L Smith,5 Alan B Thomson,6 G Vantrappen,7 Ceri J Mckenna,8 and Jane G Mills8

1St Vincent’s Hospital, Dublin, Eire, Ireland
2Sentralsykehuset i, Rogaland, Stavangar, Norway
3Drechtstedenzie-Kenhuis Refaja, Dordrecht, Netherlands
4Klinika Gastroenterologii, AM, Katowice, Poland
5Southampton General Hospital, Southampton, UK
6University of Alberta, Calgary, Alberta, Canada
7Gasthuisberg, Leuven, Belgium
8Glaxo Research and Development Limited, Greenford, UK

Received 31 October 1995; Accepted 25 March 1996

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


OBJECTIVE: To compare the efficacy and safety of long term use of ranitidine 150 mg bid, 300 mg bid and placebo in prevention of endoscopic and symptomatic relapse of reflux esophagitis in an international, double-blind, placebo controlled, parallel group study.

PATIENTS AND METHODS: A total of 279 patients at least 18 years old from hospital out-patient departments with healed esophagitis (grade 0) with no or mild symptoms entered the study. Patients were randomly allocated to receive ranitidine 150 mg, 300 mg or placebo twice daily for 48 weeks. Patients returned for symptom assessments at eight-week intervals and for re-endoscopy every 16 weeks.

RESULTS: Both ranitidine regimens were significantly more effective than placebo in preventing endoscopic and symptomatic relapse of reflux esophagitis (P=0.003 for ranitidine 150 mg bid; P<0.001 for ranitidine 300 mg bid). No statistically significant differences were observed in relapse rates between the two ranitidine regimens. The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P=0.002 for ranitidine 150 mg bid versus placebo; P<0.001 for ranitidine 300 mg bid versus placebo). Ranitidine was well tolerated.

CONCLUSIONS: Ranitidine 150 mg bid and 300 mg bid are safe and effective treatments in the prevention of reflux esophagitis relapse.